Compare Hut 8 Corp (HUT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Repligen Corporation Common Stock — how do they compare? Hut 8 Corp trades at $71.79 (market cap $10.31B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Hut 8 Corp and Repligen Corporation Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 12 Days and Repligen Corporation Common Stock for 0 Days on average.
| HUT | RGEN | |
|---|---|---|
Market Cap | $10.31B | $11.14B |
Volume | 4,904,746 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $133.02 | $194.57 |
52-Week Low | $33.76 | $102.87 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $17.74B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $83.61, down 1.91% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth projections but faces significant profitability challenges with a -188.59% net income margin. Recent developments include securing a $1.07 billion credit facility and positive analyst coverage with 94% buy ratings and a $163.62 consensus price target.
While analyst sentiment remains overwhelmingly positive, HUT faces substantial execution risks with consecutive earnings misses and negative cash flow from operations. The stock offers significant upside potential based on analyst targets but requires careful monitoring of profitability improvements and AI infrastructure contract execution.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
